💬In plain words
What the trial is, and whether it could suit you
The goal of this clinical trial is to evaluate the long-term safety and effectiveness of Ultherapy Prime (MFU-V) for improving lines, wrinkles, laxity, and crepiness of the lower face, submentum, and neck. The study will enroll adult male and female subjects aged 25-65 with moderate to severe lower-face and neck skin laxity who are appropriate candidates for non-invasive ultrasound treatment.
The main questions this study aims to answer are:
Does Ultherapy Prime delivered at multiple depths compared to a single-depth (1.5 mm) treatment improve clinical lifting, tightening, and smoothing of the lower face and neck over a 12-month period?
Does treatment with Ultherapy Prime stimulate measurable improvements in collagen-related skin quality, patient satisfaction, and investigator-assessed aesthetic outcomes?
Because the study includes two treatment approaches, researchers will compare a
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
Inclusion Criteria:
* Male or female subjects between 25 and 65 years of age at the time of screening.
Presence of moderate to severe laxity, fine lines, or crepiness of the lower face, submentum, and/or neck that is appropriate for improvement with non-invasive MFU-V treatment.
Skin condition not advanced enough to require surgical correction.
Willingness to refrain from elective aesthetic procedures involving the face, submentum, or neck for the entire 12-month duration of the study.
Ability and willingness to comply with all study visits, procedures, and follow-up requirements.
Sufficient English language proficiency to understand study instructions and complete questionnaires.
For participants of childbearing potential: negative urine pregnancy test on the day of treatment and willingness to use adequate contraception during the study.
Ability to provide written informed consent.
Exclusion Criteria:
* Male or female subjects between 25 and 65 years of age at the time of screening.
Presence of moderate to severe laxity, fine lines, or crepiness of the lower face, submentum, and/or neck that is appropriate for improvement with non-invasive MFU-V treatment.
Skin condition not advanced enough to require surgical correction.
Willingness to refrain from elective aesthetic procedures involving the face, submentum, or neck for the entire 12-month duration of the study.
Ability and willingness to comply with all study visits, procedures, and follow-up requirements.
Sufficient English language proficiency to understand study instructions and complete questionnaires.
For participants of childbearing potential: negative urine pregnancy test on the day of treatment and willingness to use adequate contraception during the study.
Ability to provide written informed consent.
Exclusion Criteria:
Active systemic or local skin disease (e.g., eczema, psoriasis, dermatitis, infection) that may affect wound healing or the evaluation of results.
Scarring, tattoos, or significant pigmentary alterations in the planned treatment areas.
Metallic implants or other implanted electronic devices (e.g., pacemakers) in or near the treatment area.
Open wounds, lesions, active herpes simplex, or active cystic/severe inflammatory acne in the treatment area.
Use of isotretinoin or other oral retinoids within the past 12 months or planned use during the study.
Microdermabrasion or medical-grade glycolic acid treatments to the treatment area within 2 weeks prior to participation.
Deep dermal scarring, thick sebaceous skin, or severe solar elastosis in the treatment area that may interfere with treatment or evaluation.
Intention to gain or lose ≥ 2 BMI units during the 12-month study period.
Known allergy or hypersensitivity to any component of the device or ultrasound coupling gel.
History of chronic drug or alcohol abuse or opioid dependence.
Recent aesthetic procedures to the lower face, submentum, or neck that may confound study outcomes (e.g., fillers, neurotoxins, lasers, threads, RF, ultrasound) within the protocol-specified washout period.
Participation in another clinical study involving an investigational device or drug within 30 days prior to treatment.
Pregnancy, breastfeeding, or plans to become pregnant during the study.
Any condition that, in the opinion of the investigator, would increase risk or interfere with study participation or data interpretation.
HealthTeky